PMR Treatment Guidelines Handout

Learn more information about treating polymyalgia rheumatica (PMR) with our free PMR Treatment Guidelines Handout.

By Wynona Jugueta on Aug 2, 2025.

Fact Checked by Gale Alagos.

Use Template

What is polymyalgia rheumatica?

Polymyalgia rheumatica (PMR) is a common condition marked by muscle stiffness and pain, primarily affecting individuals over 70, with a higher prevalence in women. The term “poly” signified many, and “myalgia” referred to muscle pain, with onset typically occurring after age 50.

Characterized by muscle pain and morning stiffness, particularly in the shoulders, hips, and neck, PMR can significantly impact daily activities. Unlike rheumatoid arthritis, PMR does not directly damage the joints. Instead, it is associated with systemic symptoms such as fatigue, fever, and weight loss.

PMR is closely linked to giant cell arteritis, another inflammatory condition that can cause headaches, jaw claudication, and vision problems. In some cases, a temporal artery biopsy is performed to diagnose giant cell arteritis. Distal tenosynovitis and carpal tunnel syndrome can also be present as features of PMR.

The diagnostic criteria of PMR are supported by the presence of elevated inflammatory markers, such as C-reactive protein (CRP) and erythrocyte sedimentation rate (ESR), along with clinical and laboratory manifestations. Previous corticosteroid treatment affect the presentation and diagnosis of the disease. In some cases, magnetic resonance imaging is used to detect characteristic inflammatory changes in PMR patients.

Management of polymyalgia rheumatica then often involves the use of corticosteroids as the initial treatment. The treatment of polymyalgia rheumatica aims to reduce inflammation and alleviate symptoms. Possible risk factors should also be addressed as a preventive measure.

PMR Treatment Guidelines Handout Template

PMR Treatment Guidelines Handout PDF Template

Use Template

Download

Download PDF Template

How to manage and treat polymyalgia rheumatica

Effective treatment improves patient quality of life and mitigates the risk of polymyalgia rheumatica and giant cell arteritis. The treatment of PMR generally revolves around corticosteroid therapy, focusing on rheumatology collaborative initiative therapies based on the patient’s symptoms and clinical manifestations.

Prednisone

Prednisone, a corticosteroid, is the cornerstone of PMR treatment. The recommended initial dose is typically 15-20 mg daily in the morning. Low-dose prednisone usually alleviates symptoms within a few days to weeks. Treatment duration varies but typically lasts 1-2 years. Some patients may require longer treatment periods. Methotrexate may be used in combination with previous corticosteroid treatment to help prevent relapses or allow the dose of prednisone to be reduced.

Painkillers

While prednisone is the primary treatment for PMR, additional pain management may be necessary, especially during the tapering phase or for breakthrough pain.

What is a PMR Treatment Guidelines Handout?

A PMR Treatment Guidelines Handout is a valuable resource designed to educate patients with polymyalgia rheumatica about their condition and its management. Our guidelines handout is based on the 2015 Recommendations for the Management of Polymyalgia Rheumatica by the European League Against Rheumatism/American College of Rheumatology Collaborative Initiative. The handout helps patients understand their condition better and the importance of adhering to treatment plans.

This educational tool is helpful in clinical practice as it helps inform discussions between healthcare providers and patients, ensuring a collaborative approach to managing arteritis and polymyalgia rheumatica.

How to use our treatment guidelines handout template?

Carepatron's treatment guidelines handout template is essential for medical professionals to educate and manage patients with PMR and giant cell arteritis. This guide outlines how to effectively utilize the handout to enhance patient understanding, adherence to treatment, and overall care.

Access the handout

To begin, medical professionals can easily access the treatment guidelines handout template through Carepatron's resource library. The handout includes key information on PMR, giant cell arteritis, and associated markers such as C-reactive protein levels.

Review the handout

Before sharing the handout with patients, it is crucial to review the content thoroughly. Ensure that all relevant clinical features.

Educate the patient with the handout

Use the handout as a comprehensive educational tool during patient consultations. Explain the importance of monitoring markers like C-reactive protein and the relevance of distinguishing between cell arteritis and polymyalgia.

Benefits of using this handout

Using Carepatron's PMR Treatment Guidelines Handout offers numerous advantages for medical professionals, enhancing the management and treatment of patients with PMR. Here are three key benefits:

Improved patient education

The handout provides clear and concise information, making it easier for patients with PMR to understand their condition. It explains complex medical terms and treatment options, such as oral prednisone and oral prednisone, in a straightforward manner.

Enhanced clinical evaluation

For medical professionals, the handout serves as a valuable tool during clinical evaluations. It offers guidance on assessing symptoms and monitoring markers such as muscle enzymes and inflammatory markers. The inclusion of data from prospective studies and randomized trials helps clinicians make informed decisions about treatment adjustments.

Streamlined follow-up and monitoring

The handout facilitates ongoing monitoring and follow-up care for patients with PMR. It outlines standardized protocols for evaluating patient progress, adjusting treatment plans, and addressing potential complications.

Commonly asked questions

The best treatment for polymyalgia rheumatica (PMR) is corticosteroids, with oral prednisone being the most commonly prescribed. These medications effectively reduce inflammation and alleviate symptoms.

The duration of prednisone treatment for PMR typically ranges from 6 months to 2 years, depending on the patient's response and tapering process. Regular monitoring by a healthcare professional is essential to adjust the dosage appropriately.

Methotrexate is often used as a steroid-sparing agent for patients who cannot tolerate prednisone or require prolonged therapy. It helps reduce the need for corticosteroids while managing symptoms.